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ABSTRACT
In spite of considerable efforts to identify effective treatments for urolithiasis, this is a goal yet to be achieved. This review 
summarizes experimental and clinical data evaluating the effect of the plant Phyllanthus niruri, a plant with worldwide 
distribution, as a potential agent to prevent and/or to treat urolithiasis The review is based on data from the literature and 
on the results obtained by our group from either in vivo/in vitro experiments or clinical studies. Phyllanthus niruri has 
been shown to interfere with many stages of stone formation, reducing crystals aggregation, modifying their structure and 
composition as well as altering the interaction of the crystals with tubular cells leading to reduced subsequent endocytosis. 
The clinical beneﬁcial effects of Phyllanthus niruri may be related to ureteral relaxation, helping to eliminate calculi or to 
clear fragments following lithotripsy, or also to a putative reduction of the excretion of urinary crystallization promoters 
such as calcium. No adverse renal, cardiovascular, neurological or toxic effects have been detected in either of these stud-
ies. Altogether, these studies suggest a preventive effect of Phyllanthus niruri in stone formation or elimination, but still 
longer-term randomized clinical trials are necessary to conﬁrm its therapeutic properties.
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INTRODUCTION
 Urinary stones affect 10-12% of the popula-
tion in industrialized countries. Their incidence has 
been increasing over the last years and the age of 
onset is decreasing. In addition, the recurrence rate 
is high, more than 50% after 10 years (1,2). Genetic, 
metabolic, environmental and dietetic factors are 
involved in the pathogenesis of urolithiasis, all of 
them propitiating the crystallization of salts inside the 
renal tubules, further retention and growing  to form 
a stone (3). Given that urine is normally a supersatu-
rated solution, crystalluria is often observed in normal 
individuals, but if crystals remain apart from each 
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other, they are washed away by urine ﬂow. However, 
under certain circumstances they bind each other due 
to chemical and electrical forces triggering the process 
of aggregation. The crystals or aggregates then attach 
to the epithelium which allow them to grow further 
and form the stone (4). Moreover, calcium oxalate 
(CaOx) crystals, the main constituent of human uri-
nary calculi, may adhere in a speciﬁc manner to the 
plasma membrane of epithelial cells and this process 
is followed by endocytosis of the crystals resulting 
in cell damage or death (5,6). Damaged cells exhibit 
a proliferative response, increase the synthesis of 
ﬁbrogenic substances promoting additional stimulus 
for crystal growth (7,8). In addition, dead cells detach 
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from the basement membrane and the cellular debris 
will adhere to other crystals resulting in a stone nidus. 
Thus, the cellular pathways involved in endocytosis of 
CaOx crystals can constitute potential targets for drugs 
designed for the prophylaxis and/or treatment of uro-
lithiasis. Different substances have been described as 
modulators of adhesion and/or endocytosis processes 
(9-11) but none of them seem to be suitable for clinical 
use. On the other hand, alternative treatments such 
as the traditional herbal treatments can compliment 
pharmacotherapies for prevention and/or treatment of 
urolithiasis with less expense and perhaps fewer side 
effects, as reviewed by Miyaoka and Monga (12).
 We have been evaluating the effects Phyl-
lanthus niruri on several stages of stone formation as 
well as its potential therapeutic potential in lithiasic 
patients. Experimental and clinical studies performed 
by our group and by others have produced interesting 
and hopeful data concerning the potential therapeutic 
use of Phyllanthus niruri to treat and/or to prevent 
stone formation. These data are summarized in this 
review.
PHYLLANTHUS NIRURI
 Phyllanthus niruri, popularly known as 
“stone-breaker” (“quebra-pedras”) is a plant belong-
ing to the Euphorbiaceae family with a worldwide 
distribution and it is used in folk Brazilian medicine 
for patients with urolithiasis (13). More than 50 
compounds were identiﬁed in the Phyllanthus niruri, 
including alkaloids, ﬂavanoids, lignans and triterpenes 
(14). Among these substances, the triterpenes have 
been found to inhibit the cytotoxicity induced by 
calcium oxalate (15) as well as to reduce excretion 
of stone forming constituents (16) and the markers 
of crystal deposition in the kidneys (17). Moreover, 
methanol extract from the leaves of Phyllanthus niruri 
containing substances such as lignans and phyllanthin 
showed a uricosuric activity in hyperuricemic rats 
(18). According to Calixto et al. (19) alkaloids ex-
tracted from plants of the genus Phyllanthus present 
an antispasmodic activity leading to smooth muscle 
relaxation, mostly evidenced in the urinary tract, 
which would facilitate the elimination of urinary 
calculi. These data strongly suggest that Phyllanthus 
niruri may be a potential source of many substances 
with antilithiasic properties.
 Interestingly, given that the maintenance of 
normal levels of calcium is critical to the function 
of many plants including plant rigidity, protection, 
detoxiﬁcation (heavy metals or oxalic acid), ion bal-
ance and even light reﬂection (20), and because high 
cellular free calcium concentration may be dangerous 
for these organisms, higher plants (plants exhibiting 
a vascular system) developed a very efﬁcient way 
to neutralize Ca+2 ions, by forming complexes with 
oxalate (21). Oxalate producing plants, which include 
many crop plants, accumulate oxalate and as much as 
90% of the total calcium in the form of CaOx crystals. 
Curiously, as shown in Figure-1, refractive CaOx 
crystals seen in the leaves of Phyllanthus niruri are 
kept equidistant, do not aggregate hence not forming 
stones. Therefore, understanding the basic molecular 
strategies by which some plants are able to package 
CaOx crystals may provide insights into the potential 
utilization of these plants to prevent/treat urolithiasis 
(22).
IN VITRO STUDIES
 The effect of the aqueous extract of Phyl-
lanthus niruri on crystallization process of CaOx in 
human urine has also been investigated in a model of 
in vitro precipitation of CaOx in human urine (23). 
Barros et al. (24) observed that the pre-incubation of 
Figure 1 – CaOx crystals observed in Phyllanthus niruri leaves 
observed under light microscopy. 
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human urine with Phyllanthus niruri did not inhibit 
the precipitation of CaOx particles and even more 
crystals were obtained in Phyllanthus niruri-contain-
ing urine, but the crystals were proportionally smaller 
than those in urine samples without Phyllanthus 
niruri. Moreover, they observed that after 24 hours, 
the precipitated crystals formed large agglomerates in 
untreated urine, but the crystals remained dispersed in 
urine with Phyllanthus niruri (Figure-2). The authors 
concluded that Phyllanthus niruri did not decrease the 
number of crystals but induced a marked reduction of 
particle size and crystal aggregation. Similar results 
were obtained by Atmani E and Khan SR (25) employ-
ing a different plant species (Herniaria hirsute), which 
is used in folk medicine in the Mediterranean area for 
its diuretic properties and to treat kidney stones. Crys-
talluria is a common event observed even in non-stone 
forming individuals. CaOx crystals are found in urine 
under several forms including monohydrate (COM) 
and dihydrate (COD) forms. Unlike COD, which is 
predominantly found in normal individuals, COM 
crystals have higher capacity to aggregate and adhere, 
and is the main form excreted by the nephrolithiasis 
patients (26-28). In the model of in vitro precipitation 
of CaOx using human urine from healthy individuals, 
Phyllanthus niruri induced an increase in COD forms 
and reduced the amount of COM crystals, responsible 
for higher potential risk for stone formation.
 Besides CaOx crystallization, it has been 
shown that the methanol extracts of Phyllanthus 
niruri showed an inhibitory activity of the enzyme 
xanthine oxidase in vitro (29) which was attributed 
to compounds such as ﬂavonoids, polyphenols and 
tannins (30,31). Therefore, together with its uricosuric 
property (18), this enzymatic inhibition activity makes 
Phyllanthus niruri a potential antihyperuricemic 
agent.
STUDIES IN CULTURED CELLS
 Campos and Schor (32) have demonstrated 
that Phyllanthus niruri exhibited a potent inhibitory 
effect on CaOx crystal adhesion and/or endocytosis 
Figure 2 – Light microscopy of CaOx crystals formed immediately (0 hr) and 24 hours after the addition of sodium oxalate solution in 
normal human urine and after in the absence and presence of Phyllanthus niruri. X100 and X400.
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by an immortalized cell line derived from canine 
kidney (MDCK cells) representative of the medullar 
collecting duct. This type of inhibitory effect occurred 
even when high doses (2.5 to 5-fold the upper limit 
in human urine) of CaOx have been employed and 
without causing cell toxicity.
EXPERIMENTAL MODELS IN RATS
 The effect of Phyllanthus niruri has also been 
evaluated in experimental models of urolithiasis in 
rats, mainly those induced by implantation of a cal-
cium oxalate (CaOx) crystal into the bladder (vesical 
foreign body method). This experimental model of 
urolithiasis is obtained with no signiﬁcant metabolic 
or systemic alterations and the vesical CaOx seed acts 
as a supporting surface allowing organic and inorganic 
material to precipitate over the central nidus, mimick-
ing a spontaneous calculus growth. It was initially 
shown that rats drinking Phyllanthus niruri tea ad 
libitum, presented decreased rate of stone growth (33). 
These effects occurred independently of any relevant 
modiﬁcation in the urinary excretion of elements 
known to promote crystallization and stone formation, 
including calcium, oxalate, uric acid, pH, etc. In order 
to evaluate if the beneﬁcial effect of Phyllanthus niruri 
could be mediated by modiﬁcations of the inhibitors 
of stone formation, such as citrate, magnesium and/or 
glycosaminoglycans, Freitas et al. (34) administered 
1.25 mg/mL/day of Phyllanthus niruri for 42 days in 
rats with vesical CaOx seed. This chronic treatment 
induced a signiﬁcant reduction in the calculi growth, 
in the absence of any modiﬁcation in the volume 
diuresis or alterations in the urinary concentration of 
lithogenic elements including calcium and oxalate. 
Phyllanthus niruri administration did not modify the 
urinary excretion of citrate and magnesium, indicating 
that the putative antilithogenic effect of Phyllanthus 
niruri was not primarily mediated by modiﬁcations 
in these inhibitors. In contrast, it was observed that 
Phyllanthus niruri induced a decrease in the urinary 
excretion of glycosaminoglycans (GAGs) compared 
with lithiasic animals receiving water. In contrast, the 
content of GAGs was higher in calculi taken from 
treated animals suggesting that the inhibitory effect 
Phyllanthus niruri on crystal growth might have been 
related to higher incorporation of GAGs into the 
calculi. The adsorption of these macromolecules into 
the calculi lead to stones with a predominant intrac-
rystalline amorphous organic matrix. Taken together, 
these results suggested that Phyllanthus niruri was 
able to prevent the aggregation of calcium oxalate to 
the pre-existent crystal without interfering with the 
incorporation of GAGs into organic matrix. Although 
the underlying mechanism remains to be clariﬁed, 
some possible hypotheses can be raised: 1) a neu-
tralization of negative charges of GAGs reduced the 
negative pole for progressive deposition of cations; 2) 
active components of  the plant could have chelated 
and/or competed with calcium for binding sites on the 
crystal surface; 3) effects of Phyllanthus niruri itself 
on other proteins including Tamm-Horsfall protein, 
nephrocalcin, osteopontin, prothrombin fragment 1, 
etc, modulating crystallization, aggregation and cal-
culi growth and 4) Phyllanthus niruri could reduce the 
crystal adhesion to the tubular epithelium. Essentially, 
these results suggest that Phyllanthus niruri could 
interfere with the calculi growth or prevent stone 
formation rather than dissolving pre-formed stones.
 In order to better mimic what is observed 
in clinical practice, Barros et al. (35) using a vesical 
foreign body model in rats, compared the efﬁcacy of 
Phyllanthus niruri treatment started concomitantly 
with CaOx seed implantation with the same treatment 
started 30 days after the seed implantation (when the 
vesical calculus was completely formed). As repre-
sented in Figure-3, the early treatment (Figure-3A) 
caused a signiﬁcant inhibition in the calculi growth 
compared with non-treated animals (Figure-3B), as 
previously observed (34). In contrast, the treatment 
initiated after the stone formation, did not prevent 
the calculi to grow further neither propitiated calculi 
elimination; however it induced drastic changes in 
the shape and texture of the preformed calculi (Fig-
ure-3C). Stones taken from Phyllanthus niruri treated 
animals were more homogeneous and contained more 
compact surfaces (Figures 3D and 3E) in contrast 
to the spicule-shaped surface taken from untreated 
animals (Figure-3F). This result suggests that Phyl-
lanthus niruri probably interferes with the biominer-
alization process, by promoting a different interaction 
between the crystal and the macromolecules of the 
organic matrix. Although Phyllanthus niruri had not 
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Figure 3 – Upper and lower panels show the stereomicroscopy and scanning electronic microscopy respectively of the calculi taken 
from animals untreated (A and D), animals treated from the beginning (B and E) and from later treated animals (C and F).
A B C 
D E F
prevented the calculi growth, the treatment resulted 
in the formation of calculi with smoother surfaces, 
which could at least, contribute to less painful calculi 
voiding.
CLINICAL STUDIES
 The initial study (33) addressing the effects 
of the Phyllanthus niruri administered in the form 
of tea did not demonstrate any clinical or biochemi-
cal adverse effects (cardiovascular, renal, hepatic or 
neurological) even at high dosage, with excellent 
tolerability in healthy volunteers. In addition, tea con-
sumption in the same dose by nephrolithiasis patients 
for a period of 3 months, led to an apparent increased 
elimination of calculi compared to patients drinking 
placebo. These results were probably ascribed to the 
antispasmodic and relaxant effects of Phyllanthus 
niruri upon ureteral muscle, facilitating calculi void-
ing.
 Subsequently, another study by Nishiura et 
al. (36), also in our Service, evaluated the effect of a 
lyophilized 2% aqueous extract of Phyllanthus niruri, 
in an additional series of 69 lithiasic patients in the 
form of 450 mg capsules (three times a day) compared 
with placebo (Chicorium sativum). In this short-term 
follow-up conducted during a three-months period, 
no signiﬁcant differences in calculi voiding and/or 
pain relief between the groups taking Phyllanthus 
niruri or the placebo were detected. However, as 
patients were classiﬁed according to the presence of 
metabolic disturbance, a signiﬁcant reduction in the 
mean urinary calcium excretion was observed only 
among hypercalciuric patients. The phytochemical 
and pharmacological properties of this plant  have 
been accounted for the action of different substances 
such as Rutin, beta-amylin, beta-sitosterol, caffeic 
acid, geranin, quercetin, niruside and repandusinic 
acid. Although none of these compounds has been 
shown to have an effect on calciuria to date, such 
potential beneﬁcial effect of Phyllanthus niruri for 
hypercalciuric patients needs to be further conﬁrmed 
in longer-term studies involving a higher number of 
subjects.
 Micali and coworkers (37) observed that 
patients submitted to extracorporeal shock wave 
lithotripsy and treated with Phyllanthus niruri during 
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3 months presented lower incidence of residual stone 
fragments, mainly those in lower calyceal location 
compared with non-treated patients. According to 
these investigators, the efﬁcacy and the lack of side 
effects of Phyllanthus help improve overall outcomes 
after extracorporeal shock wave lithotripsy and could 
be useful as either an alternative or an adjunctive 
therapy in the treatment of urolithiasis.
 Table-1 summarizes the main ﬁndings in 
all studies. Given the experimental characteristic of 
these studies, except for the clinical ones (Grade of 
recommendation B), an exact level of evidence is not 
applicable.
CONCLUSION AND PERSPECTIVES
 The experimental studies summarized here 
suggest that Phyllanthus niruri might interfere with 
important steps of the calculi formation including 
crystal aggregation and internalization by the tubular 
cells, crystal structure and composition. These proper-
ties of Phyllanthus niruri may constitute an important 
advantage in the prevention of lithiasis, inhibiting 
calculus growth and keeping the crystals dispersed 
in the urine, with their consequent easier elimination. 
Although clinical studies are less abundant, available 
data point to beneﬁcial effects of Phyllanthus by in-
ducing ureteral relaxation, interfering in the excretion 
Table 1 – Summary of main ﬁndings.
Studies Main Findings Reference
Models in vitro Inhibition of CaOx crystal adhesion and/or endocytosis
Reduction in crystals aggregation
Increase in COD forms and reduced COM crystals
32
24
24
Models in vivo Decreased rate of stone growth
Increase intracrystalline amorphous organic matrix
Changes in the shape and texture of the preformed calculi
34,35
34
35
Clinical Increased calculi voiding
Reduction in urinary calcium excretion in hypercalciuric patients
Reduction in residual stone fragments after extracorporeal shock 
wave lithotripsy
33
36
37
COM = calcium oxalate monohydrate; COD = calcium oxalate dihydrate.
of promoters of urinary crystallization such as calcium 
or helping to clear fragments following lithotripsy. It 
is important to consider however, that although it is 
clear that Phyllanthus niruri can interfere with many 
steps of the stone formation, longer-term clinical stud-
ies are necessary to deﬁne whether these effects can 
be translated into real clinical beneﬁt to treat and/or 
prevent urolithiasis.
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EDITORIAL COMMENT
 The authors provide a nice review on the herb 
Phyllanthus niruri whose properties appear in fact to 
be promising assets in stone disease prevention and 
treatment. However, care must be taken to properly 
design future clinical studies in a way to provide re-
liable, consistent and reproducible data. As a major 
concern, I would point out the deﬁnition of accurate 
dosage and mode of intake. In a recent review on Chi-
nese herbs used for managing stone disease, Miyaoka 
et al. (1) found several clinical trials demonstrating the 
likely beneﬁts on stone prevention. However, the lack 
of standardization on dose and compounds between 
studies evaluating the same herbs made it extremely 
difﬁcult to compare them and draw a sustainable 
conclusion. As a result, although used for hundreds 
of years with practical evidence of clinical beneﬁts, 
Chinese herbs still strive to enter the armamentarium 
of stone therapy as a global consensus.
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